-
Signature
-
/s/ Charles Schoch, as Attorney-in-Fact for Seshu Tyagarajan
-
Issuer symbol
-
CADL
-
Transactions as of
-
26 Jan 2026
-
Net transactions value
-
$0
-
Form type
-
4
-
Filing time
-
28 Jan 2026, 17:04:50 UTC
Quoteable Key Fact
"Seshu Tyagarajan filed Form 4 for Candel Therapeutics, Inc. (CADL) on 28 Jan 2026."
Quick Takeaways
- This page summarizes Seshu Tyagarajan's Form 4 filing for Candel Therapeutics, Inc. (CADL).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 28 Jan 2026, 17:04.
What Changed
- Previous filing in this sequence was filed on 26 Jun 2025.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Tyagarajan Seshu |
Chief Technology Officer |
C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM |
/s/ Charles Schoch, as Attorney-in-Fact for Seshu Tyagarajan |
28 Jan 2026 |
0001923794 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CADL |
Stock Option (Right to Buy) |
Award |
$0 |
+154,000 |
|
$0.000000 |
154,000 |
26 Jan 2026 |
Common Stock |
154,000 |
$6.01 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses: